Trubion Pharmaceuticals is selling itself too cheaply through an unfair process to Emergent BioSolutions, for $4.55 a share plus 0.1641 shares of Emergent stock for each Trubion share, a $97 million deal, shareholders say in King County Court, Seattle.
Categories / Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
-
Texans head to the polls for high-stakes US Senate primary February 17, 2026